COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk said on Thursday it would take legal action against Hims & ‌Hers after the online telehealth ​company said it will begin ‍offering compounded copies of ⁠the ⁠Danish group's Wegovy pill at an ‌introductory price ​of $49 per month.

"The action by Hims & Hers is ⁠illegal mass ‍compounding ​that poses a significant risk to patient safety," the Danish ‍drugmaker said in a statement.

"Novo Nordisk will take legal and regulatory action to protect patients, our ​intellectual ‍property and the integrity of the U.S. gold-standard ​drug approval framework," it added.

Novo Nordisk said it was the only company that manufactured an FDA-approved Wegovy pill formulated with ​SNAC technology, which facilitates semaglutide absorption when administered orally.